Recently, the Chongqing Ureteral Stricture Symposium was successfully held, bringing together leading urologists from Southwest China to discuss the latest advances in minimally invasive endourological management of complex ureteral strictures. EVT Medical showcased its self-developed Ureteral Stent System, engaging with clinical experts on innovative treatment strategies.

During the scientific session, Professor Jie Li from the First Affiliated Hospital of Chongqing Medical University shared his extensive clinical experience and presented a series of representative cases. Based on his real-world clinical practice, Professor Li spoke highly of the EVT Ureteral Stent System, noting that it demonstrated excellent overall clinical performance and, in his experience, outperformed the imported Allium® ureteral stent in several key aspects, making it a valuable option for broader clinical adoption.

Ureteral stricture remains one of the most challenging conditions in urology. Conventional treatment options are often associated with recurrent stenosis, stent migration, and frequent stent replacement. Covered metallic ureteral stents have become an important therapeutic option for complex strictures due to their strong radial force, resistance to tissue ingrowth, and suitability for long-term implantation. However, this segment has long been dominated by imported products.

Designed with the anatomical characteristics of Chinese patients in mind, the EVT Ureteral Stent System has been continuously optimized to enhance flexibility, deployment accuracy, resistance to encrustation, and long-term patency. As clinical experience continues to grow, the system has gained increasing recognition from frontline urologists for its reliable performance in routine and complex cases.

During the symposium, numerous experts visited the EVT Medical booth to exchange insights on implantation techniques, patient selection for complex cases, long-term follow-up, and future product development.

Looking ahead, EVT Medical remains committed to advancing innovation in urological intervention. Driven by clinical needs, the company will continue to develop high-quality minimally invasive technologies and provide safer, more effective treatment solutions for patients with ureteral strictures worldwide.